CARSGEN-B Surges Over 32% Following Earnings Release, Annual Loss Narrows by 87.7%

Deep News03-09

CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of HK$47.71 million.

On March 6, CARSGEN-B released its annual results for the period ending December 31, 2025. The company reported revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. Basic loss per share was RMB 0.18. For the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CytoCART® (an autologous BCMA CAR-T cell therapy). Notably, the revenue from CytoCART® was calculated based on the ex-factory price rather than the end-market price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114135542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114135542","market":"nz","top_or_hot":-1,"title":"CARSGEN-B Surges Over 32% Following Earnings Release, Annual Loss Narrows by 87.7%","media":"Deep News","content":"<p>CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of HK$47.71 million.</p>\n<p>On March 6, CARSGEN-B released its annual results for the period ending December 31, 2025. The company reported revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. Basic loss per share was RMB 0.18. For the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CytoCART® (an autologous BCMA CAR-T cell therapy). Notably, the revenue from CytoCART® was calculated based on the ex-factory price rather than the end-market price.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Surges Over 32% Following Earnings Release, Annual Loss Narrows by 87.7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Surges Over 32% Following Earnings Release, Annual Loss Narrows by 87.7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-03-09 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of HK$47.71 million.</p>\n<p>On March 6, CARSGEN-B released its annual results for the period ending December 31, 2025. The company reported revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. Basic loss per share was RMB 0.18. For the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CytoCART® (an autologous BCMA CAR-T cell therapy). Notably, the revenue from CytoCART® was calculated based on the ex-factory price rather than the end-market price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1114135542","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114135542","pubTimestamp":1773021104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B"},"translate_title":"科济源-B财报发布后飙升逾32%，年度亏损收窄87.7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of HK$47.71 million.\nOn March 6, CARSGEN-B released its annual results for the period ending December 31, 2025. The company reported revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. Basic loss per share was RMB 0.18. For the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CytoCART® (an autologous BCMA CAR-T cell therapy). Notably, the revenue from CytoCART® was calculated based on the ex-factory price rather than the end-market price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114135542","isCrawlerRequest":true}